These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8700540)

  • 1. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.
    Sonoda H; Nishida K; Yoshioka T; Ohtani M; Sugita K
    Oncogene; 1996 Jul; 13(1):143-9. PubMed ID: 8700540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
    Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
    Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of tropomyosin-2 expression in c-Jun-transformed rat fibroblasts involves induction of a MEK1-dependent autocrine loop.
    Ljungdahl S; Linder S; Franzén B; Binétruy B; Auer G; Shoshan MC
    Cell Growth Differ; 1998 Jul; 9(7):565-73. PubMed ID: 9690624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
    Rapp UR; Troppmair J; Beck T; Birrer MJ
    Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.
    Kieser A; Seitz T; Adler HS; Coffer P; Kremmer E; Crespo P; Gutkind JS; Henderson DW; Mushinski JF; Kolch W; Mischak H
    Genes Dev; 1996 Jun; 10(12):1455-66. PubMed ID: 8666230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
    Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
    Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
    He H; Hirokawa Y; Levitzki A; Maruta H
    Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
    Barradas M; Monjas A; Diaz-Meco MT; Serrano M; Moscat J
    EMBO J; 1999 Nov; 18(22):6362-9. PubMed ID: 10562548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.
    Büscher D; Dello Sbarba P; Hipskind RA; Rapp UR; Stanley ER; Baccarini M
    Oncogene; 1993 Dec; 8(12):3323-32. PubMed ID: 8247534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
    Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
    Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
    Topol LZ; Marx M; Calothy G; Blair DG
    Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes.
    Reed JC; Yum S; Cuddy MP; Turner BC; Rapp UR
    Cell Growth Differ; 1991 May; 2(5):235-43. PubMed ID: 1888699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.
    Su Z; Shi Y; Friedman R; Qiao L; McKinstry R; Hinman D; Dent P; Fisher PB
    Nucleic Acids Res; 2001 Apr; 29(8):1661-71. PubMed ID: 11292838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter.
    Hussain S; Kilbey A; Gillespie DA
    Cell Growth Differ; 1998 Aug; 9(8):677-86. PubMed ID: 9716184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct involvement of cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells.
    Olivo C; Vanni C; Mancini P; Silengo L; Torrisi MR; Tarone G; Defilippi P; Eva A
    Oncogene; 2000 Mar; 19(11):1428-36. PubMed ID: 10723134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.